Apalutamide Patent Expiration

Apalutamide is Used for treating various forms of prostate cancer, including non-metastatic and metastatic types, in combination with different therapies. It was first introduced by Janssen Biotech Inc in its drug Erleada on Feb 14, 2018.


Apalutamide Patents

Given below is the list of patents protecting Apalutamide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Erleada US10052314 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep 23, 2033 Janssen Biotech
Erleada US10702508 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer Apr 30, 2038 Janssen Biotech
Erleada US10849888 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep 23, 2033 Janssen Biotech
Erleada US11963952 Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer Jan 30, 2040 Janssen Biotech
Erleada US8445507 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases Sep 15, 2030 Janssen Biotech
Erleada US8802689 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases Mar 27, 2027 Janssen Biotech
Erleada US9388159 Substituted diazaspiroalkanes as androgen receptor modulators Mar 27, 2027 Janssen Biotech
Erleada US9481663 Crystalline forms of an androgen receptor modulator Jun 04, 2033 Janssen Biotech
Erleada US9884054 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep 23, 2033 Janssen Biotech
Erleada US9987261 Substituted diazaspiroalkanes as androgen receptor modulators Mar 27, 2027 Janssen Biotech
Erleada USRE49353 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep 23, 2033 Janssen Biotech


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳